首页> 美国卫生研究院文献>Diseases >Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis
【2h】

Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis

机译:非恶性前列腺疾病:BPH和慢性前列腺炎的男性对治疗设备启用的热平衡疗法的积极反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: The most common types of non-malignant prostate diseases are benign prostatic hyperplasia (BPH) and chronic prostatitis (CP). The aim of this study was to find out whether thermobalancing therapy with a physiotherapeutic device is effective for BPH and CP. Methods: During a 2.5-year period, 124 men with BPH over the age of 55 were investigated. Clinical parameters were tested twice: via the International Prostate Symptom Score (IPSS) and via ultrasound measurement of prostate volume (PV) and uroflowmetry maximum flow rate (Qmax), before and after six months of therapy. In 45 men with CP under the age of 55, the dynamics of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) were studied. Results: The results of the investigated index tests in men with BPH confirmed a decrease in IPSS (p < 0.001), a reduction in PV (p < 0.001), an increase in Qmax (p < 0.001), and an improvement of quality of life (QoL) (p < 0.001). NIH-CPSI scores in men with CP indicated positive dynamics. Conclusions: The observed positive changes in IPSS, PV, and Qmax in men with BPH and the improvement in NIH-CPSI-QoL in patients with CP after using a physiotherapeutic device for six months as mono-therapy, support the view that thermobalancing therapy with the device can be recommended for these patients. Furthermore, the therapeutic device is free of side effects.
机译:背景:非恶性前列腺疾病最常见的类型是良性前列腺增生(BPH)和慢性前列腺炎(CP)。这项研究的目的是发现采用物理治疗仪的热平衡疗法对BPH和CP是否有效。方法:在2.5年期间,对124名55岁以上的BPH男性进行了调查。在治疗六个月之前和之后,对临床参数进行了两次测试:通过国际前列腺症状评分(IPSS)以及通过超声测量前列腺体积(PV)和尿流率最大流速(Qmax)。在45名55岁以下CP的男性中,研究了美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)的动态。结果:对BPH男性进行的研究指标测试结果证实IPSS降低(p <0.001),PV降低(p <0.001),Qmax升高(p <0.001),并且质量得到改善。寿命(QoL)(p <0.001)。患有CP的男性的NIH-CPSI评分显示出积极的动态。结论:在使用物理治疗仪六个月的单药治疗中,观察到的BPH男性IPSS,PV和Qmax的阳性变化以及CP患者NIH-CPSI-QoL的改善,支持以下观点:该设备可以推荐给这些患者。此外,治疗装置没有副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号